FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis

Rhea-AI Summary

FibroBiologics (Nasdaq: FBLG) announced issuance of U.S. Patent No. 12,544,407 B2, dated February 10, 2026, covering fibroblast cell therapy for osteoporosis. The patent claims systemic and local administration, modified/dedifferentiated fibroblasts (OCT4, NANOG, SOX2), recombinant CXCR4/hTERT, marker-selected cells, and combination use with anti-inflammatory agents.

This issuance strengthens the company’s intellectual property in regenerative medicine and bone disorders and supports its strategy to develop proprietary fibroblast therapies addressing osteoporosis and related bone diseases.

Positive

• U.S. patent issued (No. 12,544,407 B2) dated February 10, 2026
• Broad claims covering systemic/local administration and modified fibroblasts
• Claims include recombinant CXCR4 and hTERT, dedifferentiated fibroblasts, and marker-selected cells

Negative

• No clinical efficacy or regulatory approval data disclosed in this announcement

News Market Reaction – FBLG

+27.66% 3.2x vol

30 alerts

+27.66% News Effect

+57.9% Peak in 25 hr 48 min

+$7M Valuation Impact

$32M Market Cap

3.2x Rel. Volume

On the day this news was published, FBLG gained 27.66%, reflecting a significant positive market reaction. Argus tracked a peak move of +57.9% during that session. Our momentum scanner triggered 30 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $7M to the company's valuation, bringing the market cap to $32M at that time. Trading volume was very high at 3.2x the daily average, suggesting strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Patent portfolio size: 270+ patents issued and pending U.S. patent number: U.S. Patent No. 12,544,407 B2 Price change: 16.15% +2 more

5 metrics

Patent portfolio size 270+ patents issued and pending FibroBiologics total IP estate mentioned in release

U.S. patent number U.S. Patent No. 12,544,407 B2 Osteoporosis fibroblast cell therapy patent issued Feb 10, 2026

Price change 16.15% 24h move in FBLG prior to this news

52-week range $0.2201 – $1.53 Low and high before this announcement

Market cap $18,818,429 Equity value prior to the patent news

Market Reality Check

Price: $0.4163 Vol: Volume 1,261,456 is 1.29x...

normal vol

$0.4163 Last Close

Volume Volume 1,261,456 is 1.29x the 20-day average of 978,573, indicating elevated activity ahead of this patent news. normal

Technical Price at $0.3286 is trading below the 200-day MA of $0.50 and remains 78.52% under the 52-week high of $1.53.

Peers on Argus

FBLG showed a 16.15% gain while only one peer (GDTC) appeared in momentum scans,...

1 Down

FBLG showed a 16.15% gain while only one peer (GDTC) appeared in momentum scans, moving down 7.42%, suggesting today’s move is stock-specific rather than a coordinated biotech sector rotation.

Historical Context

5 past events · Latest: 2026-02-26 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
2026-02-26	Conference presentation	Positive	+7.4%	CEO scheduled to present and meet investors at BIO Investment & Growth Summit.
2026-02-24	Earnings and update	Positive	-1.6%	Full-year 2025 results, pipeline progress, capital raise and debt repayment details.
2026-02-23	Nasdaq extension	Positive	+2.0%	Nasdaq Hearings Panel granted more time to regain listing compliance thresholds.
2026-02-10	Leadership presentation	Positive	+6.2%	CEO selected to present at A4LI’s H-SPAN Summit on longevity and policy.
2026-02-05	Patent issuance	Positive	-9.2%	Canadian patent granted for fibroblast-based cachexia treatment, expanding IP portfolio.

Pattern Detected

News has often produced positive moves, but patent and fundamental updates have twice seen negative follow-through, indicating occasional divergence between seemingly positive catalysts and price reaction.

Recent Company History

Over the last month, FibroBiologics has reported several developments, including Canadian patent issuance for cachexia on Feb 5, a Nasdaq compliance extension on Feb 23, a 2025 results and corporate update on Feb 24, and upcoming conference presentations. Reactions varied: the Canadian patent and full-year update saw declines of -9.2% and -1.57%, while conference and compliance news generated gains between 2.02% and 7.44%. Today’s osteoporosis patent fits the pattern of IP-focused releases within an active news flow.

Market Pulse Summary

The stock surged +27.7% in the session following this news. A strong positive reaction aligns with F...

Analysis

The stock surged +27.7% in the session following this news. A strong positive reaction aligns with FibroBiologics’ pattern of favorable responses to conference and compliance updates, though past patent news saw mixed outcomes. With shares at $0.3286, still well below the $1.53 52-week high and under the $0.50 200-day MA, prior financings and Nasdaq listing conditions remain key overhangs that could influence how durable enthusiasm around new IP, such as U.S. Patent No. 12,544,407 B2, proves over time.

Key Terms

fibroblast cell therapy, osteoporosis, osteoclast, osteoblast, +4 more

8 terms

fibroblast cell therapy medical

"A new U.S. patent entitled “Fibroblast Cell Therapy for Treatment of Osteoporosis.”"

A therapy that uses fibroblast cells—natural cells that build and repair connective tissue like skin and scars—to promote healing or restore damaged tissue. For investors, it matters because these treatments can offer lasting, biologically based solutions with potential for premium pricing and market demand, but they also carry high clinical-development, manufacturing and regulatory risks similar to other cell therapies, so success depends on proven safety, efficacy and scalable production.

osteoporosis medical

"Fibroblast Cell Therapy for Treatment of Osteoporosis.”"

A condition in which bones become thinner and more fragile, making them more likely to break — imagine normal bone turning from solid wood into a brittle sponge. For investors, osteoporosis matters because it creates sustained demand for drugs, diagnostic tests, implants and supportive care, and can influence revenues, regulatory reviews and clinical-trial outcomes in companies involved in bone health and aging-related services.

osteoclast medical

"modulate bone remodeling by inhibiting osteoclast activity and/or promoting osteoblast"

Osteoclasts are specialized cells that break down and remove old or damaged bone, acting like a demolition crew that clears space for new bone to form. They matter to investors because many drugs and medical devices aim to slow, stop, or modulate their activity to treat bone diseases—so changes in osteoclast-related science, clinical trial results, or regulatory guidance can directly affect a company’s drug prospects, market size, and revenue forecasts.

osteoblast medical

"inhibiting osteoclast activity and/or promoting osteoblast activity."

Osteoblast is a type of cell that builds and hardens bone, like a construction crew laying bricks and cement to create a sturdy structure. For investors, osteoblast activity matters because therapies or devices that change how these cells work can affect treatment success in bone diseases and healing, which influences clinical trial outcomes, regulatory approval chances, and the commercial value of related medical products.

cxcr4 medical

"fibroblasts expressing recombinant CXCR4 or recombinant hTERT."

CXCR4 is a protein on the surface of many cells that acts like a lock for a specific chemical signal, guiding cells where to go and how to behave. It matters to investors because drugs that block or mimic this receptor can change immune responses, stop cancer cells from spreading, help mobilize stem cells for transplants, or affect viral entry; thus CXCR4-targeted therapies can drive clinical value, regulatory milestones, and licensing or partnership opportunities.

htert medical

"fibroblasts expressing recombinant CXCR4 or recombinant hTERT."

hTERT is the protein that forms the active part of telomerase, the enzyme that helps cells rebuild the protective caps on their chromosomes so they can keep dividing. Investors care because changes in hTERT activity are linked to cancer growth, regenerative medicine and diagnostic tests, so therapies or tests targeting hTERT can drive a biotech company’s valuation, regulatory risk, and revenue potential much like a single key component can determine the fate of a whole machine.

rank ligand (rankl) medical

"including inhibition of RANK ligand (RANKL)-mediated osteoclast activation."

RANK ligand (RANKL) is a signaling protein that tells certain bone cells (osteoclasts) to form and eat away bone, and it also helps regulate some immune responses. Investors care because drugs that block or modify RANKL can slow bone loss, reduce fractures, or limit bone damage from cancers, so changes in RANKL-related research, approvals, or sales can materially affect healthcare companies and their prospects.

nf-kappa b medical

"Combination therapy with anti-inflammatory agents, including NF-kappa B inhibitors"

A family of proteins that act like cellular switches, turning groups of genes on or off in response to stress, infection, or injury; they play a central role in controlling inflammation, immune responses, and cell survival. For investors, NF-kappa B matters because it is a common target in drug development and diagnostics—changes in its activity can affect disease progression, trial outcomes, safety profiles and the commercial potential of therapies, much like a thermostat that influences an entire building’s climate.

AI-generated analysis. Not financial advice.

HOUSTON, March 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the issuance of a new U.S. patent entitled “Fibroblast Cell Therapy for Treatment of Osteoporosis.”

The United States Patent and Trademark Office has issued U.S. Patent No. 12,544,407 B2, dated February 10, 2026, further strengthening FibroBiologics’ intellectual property portfolio in regenerative medicine and bone-related disorders.

The patent covers methods of treating bone diseases or disorders, including osteoporosis, through the administration of fibroblast cells. The claims encompass systemic or local administration of fibroblasts, including modified fibroblasts, to modulate bone remodeling by inhibiting osteoclast activity and/or promoting osteoblast activity.

Specifically, the issued patent includes claims directed to:

• Methods of treating osteoporosis through administration of fibroblasts expressing recombinant CXCR4 or recombinant hTERT.
• Dedifferentiated fibroblasts generated through expression of OCT4, NANOG, and/or SOX2.
• Fibroblasts selected for specific marker profiles, including CD73, CD56, CD140, CD105, CD90, CD36, and CD146.
• Administration of fibroblasts systemically or locally.
• Combination therapy with anti-inflammatory agents, including NF-kappa B inhibitors
  
  

Osteoporosis is a chronic and progressive condition characterized by reduced bone mass and structural deterioration of bone tissue, leading to increased fracture risk. The newly issued patent supports FibroBiologics’ approach to leveraging fibroblasts as therapeutic agents capable of modulating bone resorption and bone formation pathways, including inhibition of RANK ligand (RANKL)-mediated osteoclast activation.

“This patent is more than a milestone, it’s a bold step forward in our mission to rethink what’s possible in regenerative medicine,” said Pete O’Heeron, Founder and Chief Executive Officer of FibroBiologics. “Osteoporosis impacts millions of lives across the globe, often quietly and profoundly. We see fibroblasts not just as cells, but as catalysts for change, with the potential to transform the way we treat bone degeneration by tackling both inflammation and the rebuilding process at its core. That’s the kind of innovation that truly excites us.”

With this issuance, FibroBiologics further reinforces its strategy of developing proprietary fibroblast cell therapies designed to address significant unmet medical needs.

For more information, please visit FibroBiologics’ website, email FibroBiologics at info@fibrobiologics.com or follow FibroBiologics on LinkedIn, YouTube, Facebook or X.

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the scope and strength of the Company’s intellectual property portfolio, the potential indications for FibroBiologics’ programs, and the potential clinical benefits of fibroblasts and fibroblast-derived materials in regenerative medicine and bone-related disorders, including osteoporosis. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of FibroBiologics’ R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

FAQ

What does FibroBiologics' U.S. patent No. 12,544,407 B2 cover for osteoporosis (FBLG)?

It covers methods of treating osteoporosis using fibroblast cells, including modified and dedifferentiated fibroblasts. According to the company, claims include recombinant CXCR4 or hTERT expression, OCT4/NANOG/SOX2 dedifferentiation, and marker-selected fibroblast profiles.

When was the FibroBiologics osteoporosis patent (FBLG) issued and why is the date important?

The patent was issued on February 10, 2026, as U.S. Patent No. 12,544,407 B2. According to the company, the issuance formally expands its IP estate and secures specific therapeutic methods relevant to bone remodeling.

How might FibroBiologics' new patent (FBLG) affect its intellectual property strength?

The patent broadens IP around fibroblast-based bone therapies, reinforcing protection for key methods and cell types. According to the company, it strengthens their portfolio across regenerative medicine and bone-related disorder claims.

Does the FibroBiologics patent (FBLG) include combination therapy approaches for osteoporosis?

Yes, the patent explicitly includes combination therapy with anti-inflammatory agents such as NF-kappa B inhibitors. According to the company, claims cover combining fibroblast administration with anti-inflammatory drugs to modulate bone remodeling.

Does the patent issuance mean FibroBiologics (FBLG) has an approved osteoporosis treatment now?

No, patent issuance protects intellectual property but is not regulatory approval for treatment use. According to the company, the patent supports development but does not equate to clinical efficacy or market authorization.

What specific fibroblast characteristics are claimed in FibroBiologics' osteoporosis patent (FBLG)?

Claims include fibroblasts selected for markers like CD73, CD56, CD140, CD105, CD90, CD36, and CD146. According to the company, marker-selected cells and modified fibroblasts are covered for modulating osteoclast and osteoblast activity.